2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
Aguirre L, Jain A, Ball S, Ali N, Volpe V, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 459-467. PMID: 38548563, DOI: 10.1016/j.clml.2024.03.001.Peer-Reviewed Original ResearchConceptsRate of leukemic transformationResponse to ruxolitinibLeukemic transformationPercentage of marrow blastsAssessment of treatment responseH. Lee Moffitt Cancer CenterPhenotypic driver mutationsNegative myeloproliferative neoplasmsHigh-risk diseaseAggressive clinical behaviorDiagnosis of myelofibrosisProportion of patientsOverall survival timeMoffitt Cancer CenterShort durationMarrow blastsTrisomy 8Epigenetic modificationsTN patientsAggressive courseRisk diseaseClinical presentationMyeloproliferative neoplasmsInferior outcomesClinical behavior
2023
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2020
Molecular and clinicopathologic characterization of intravenous leiomyomatosis
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisAggressive clinical behaviorClinical behaviorArray comparative genomic hybridizationCyclin D1Uterine smooth muscle tumorsSmooth muscle tumorsSmooth muscle proliferationRecurrent chromosome alterationsCommon genetic alterationsFH immunohistochemistryClinicopathologic characterizationImmunohistochemical findingsMesenchymal tumorsMuscle tumorsBenign appearanceMuscle proliferationUterine leiomyomaGroup 1Group 3Nonneoplastic tissuesIndex scoreVascular morphologyProtein expressionComparative genomic hybridization
2019
Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles
Buza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Modern Pathology 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, MissedAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChromosomes, Human, Pair 11CyclophosphamideDactinomycinEtoposideFemaleGenetic LociGenetic Predisposition to DiseaseHumansHydatidiform MoleMaleMethotrexatePhenotypePregnancyTreatment OutcomeTyrosine 3-MonooxygenaseUniparental DisomyUterine NeoplasmsVincristineConceptsPaternal uniparental isodisomyAbnormal trophoblastic proliferationCases of gestationUneventful clinical courseAggressive clinical behaviorUniparental isodisomyTyrosine hydroxylase locusMultiagent chemotherapyClinical courseFirst trimesterClinical complicationsImmunohistochemical featuresClinical behaviorMissed abortionAbnormal gestationsTyrosine hydroxylasePatientsTrophoblastic proliferationVillous cytotrophoblastsStromal cellsPhenotypical presentationChorionic villiGenetic conditionsP57 expressionGestationNational trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.Peer-Reviewed Original ResearchUse of NACUrothelial cell carcinomaReceipt of NACNeoadjuvant chemotherapyMicropapillary variantPathologic responseEntire cohortCell carcinomaClinical stage II diseasePropensity scoreVariant urothelial carcinomaNational Cancer DatabaseStage II diseaseComplete pathologic responsePathologic complete responseAggressive clinical behaviorLogistic regression modelsCT2 diseasePT0 rateComplete responsePathologic characteristicsRadical cystectomyDistant metastasisHistological diagnosisNAC use
2016
Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms
Lazova R, Seeley EH, Kutzner H, Scolyer RA, Scott G, Cerroni L, Fried I, Kozovska ME, Rosenberg AS, Prieto VG, Shehata BM, Durham MM, Henry G, Rodriguez-Peralto JL, Riveiro-Falkenbach E, Schaefer JT, Danialan R, Fraitag S, Vollenweider-Roten S, Sepehr A, Sangueza M, Hijazi N, Corredoira Y, Kowal R, Harris OM, Bravo F, Boyd AS, Gueorguieva R, Caprioli RM. Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. Journal Of The American Academy Of Dermatology 2016, 75: 1176-1186.e4. PMID: 27502312, PMCID: PMC5112112, DOI: 10.1016/j.jaad.2016.07.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overChildChild, PreschoolDiagnosis, DifferentialFemaleHumansLymphatic MetastasisMaleMass SpectrometryMelanomaMiddle AgedNeoplasm Recurrence, LocalNevus, Epithelioid and Spindle CellProteinsRetrospective StudiesRisk AssessmentSentinel Lymph Node BiopsySkin NeoplasmsTreatment OutcomeTumor BurdenYoung AdultConceptsAtypical spitzoid neoplasmsClinical group 1Clinical behaviorSpitzoid melanomaHistopathological diagnosisGroup 1Spitzoid neoplasmsClinical group 2Greater tumor thicknessRetrospective collaborative studyAggressive clinical behaviorClinical outcomesRisk stratificationTumor thicknessPoor outcomeWorse clinical behaviorGroup 2Older ageClinical groupsDiagnosisSpitz neviMelanomaStrong associationProteomic signaturePatients
2014
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 2014, 32: 29-38. PMID: 25398397, PMCID: PMC4310789, DOI: 10.1007/s10585-014-9688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCarcinosarcomaCell Line, TumorCell ProliferationFemaleImmunoconjugatesM Phase Cell Cycle CheckpointsMaytansineMiceMice, SCIDOvarian NeoplasmsReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsCS cell linesT-DM1Cell linesFlow cytometryNovel antibody-drug conjugateAggressive clinical behaviorNovel treatment optionsG2/M phase cell cycle arrestHER2 protein overexpressionM phase cell cycle arrestPhase cell cycle arrestAntibody-drug conjugatesDisease refractoryPrimary HER2Vehicle miceOvarian carcinosarcomaPoor prognosisUterine carcinosarcomaCS patientsTreatment optionsClinical behaviorLonger survivalCell cycle arrestHER2 amplificationCarcinosarcoma
2009
Extragenital adenosarcoma: A case report, review of the literature, and management discussion
Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: A case report, review of the literature, and management discussion. Gynecologic Oncology 2009, 115: 472-475. PMID: 19712965, PMCID: PMC4451226, DOI: 10.1016/j.ygyno.2009.07.033.Peer-Reviewed Case Reports and Technical NotesConceptsSarcomatous overgrowthLiposomal doxorubicinHigh-grade bowel obstructionMixed epithelial-mesenchymal tumorsComplete clinical responseInitial cytoreductive surgeryCompletion of chemotherapyFavorable prognostic factorAggressive clinical behaviorCoexistent endometriosisConcurrent endometriosisBowel obstructionCytoreductive surgeryClinical responseExtragenital sitesPrognostic factorsCase reportClinical behaviorSecond surgeryMüllerian adenosarcomaRare caseAdenosarcomaEndometriosisChemotherapySurgery
1995
Report of Eight Cases and Review of the Literature
Hasserjian R, Klimstra D, Rosai J. Report of Eight Cases and Review of the Literature. The American Journal Of Surgical Pathology 1995, 19: 835-841. PMID: 7793482, DOI: 10.1097/00000478-199507000-00012.Peer-Reviewed Original ResearchConceptsClear-cell featuresThymic carcinomaClear-cellCases of thymic carcinomaHigh-grade thymic carcinomasMetastatic clear-cell carcinomaSheet-like growth patternHigh-molecular-weight keratinPrimary thymic carcinomaDead of diseaseClear-cell carcinomaEpithelial membrane antigenAggressive clinical behaviorClear-cell neoplasmsMediastinal seminomaPlacental alkaline phosphataseParathyroid carcinomaPersistent diseaseMembrane antigenClinical behaviorTumor cellsDifferential diagnosisFollow-upCarcinomaNuclear features
1988
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas
Kacinski B, Carter D, Mittal K, Kohorn E, Bloodgood R, Donahue J, Donofrio L, Edwards R, Schwartz P, Chambers J, Chambers S. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. International Journal Of Radiation Oncology • Biology • Physics 1988, 15: 823-829. PMID: 3182322, DOI: 10.1016/0360-3016(88)90113-7.Peer-Reviewed Original ResearchConceptsEndometrial currettingsDeep myometrial penetrationStage I patientsAggressive clinical behaviorHuman endometrial adenocarcinomaMicron paraffin sectionsMyometrial penetrationLocoregional spreadClinicopathologic featuresEndometrial adenocarcinomaI patientsPoor outcomeEndometrial specimensClinical behaviorInvasive adenocarcinomaBenign hyperplasiaAdenocarcinomaMalignant phenotypeParaffin sectionsM-CSFM-CSF receptorOncogene expressionProto-oncogene mRNAKi-rasPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply